Atossa Therapeutics logo
Atossa Therapeutics ATOS
$ 5.33 3.9%

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Atossa Therapeutics Net Debt 2011-2026 | ATOS

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Atossa Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - -39.6 M -12.5 M -10.4 M -7.22 M -3.03 M -3.72 M -8.38 M -6.32 M -1.73 M -906 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-906 K -39.6 M -9.38 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
Benitec Biopharma Benitec Biopharma
BNTC
-1.92 M $ 10.98 -4.52 % $ 452 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
-15.2 M $ 1.36 -20.0 % $ 45.5 M canadaCanada
Pharming Group N.V. Pharming Group N.V.
PHAR
-43.5 M $ 15.36 -0.71 % $ 7.59 B niderlandNiderland
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Inventiva S.A. Inventiva S.A.
IVA
-95.6 M $ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
-3.94 M $ 1.21 -3.97 % $ 71.5 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
-15.7 M $ 2.28 -0.44 % $ 1.03 M israelIsrael
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Assembly Biosciences Assembly Biosciences
ASMB
-55.8 M $ 28.46 3.45 % $ 319 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.37 -4.2 % $ 350 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-205 M $ 156.92 -1.23 % $ 7.81 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.4 -3.68 % $ 1.02 B canadaCanada
Atreca Atreca
BCEL
33.1 M - -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M - -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-3.56 B - 0.49 % $ 251 B cayman-islandsCayman-islands
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
-1.3 B $ 54.13 -1.64 % $ 10.4 B usaUSA
Calithera Biosciences Calithera Biosciences
CALA
-56.5 M - -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-9.78 M - -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
-42.5 M - - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-23.8 M - -74.18 % $ 955 K usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
-5.05 M $ 2.09 -0.95 % $ 195 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
-85.6 M $ 1.52 -5.59 % $ 178 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
-40.8 M - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
293 M - -7.23 % $ 13 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 7.7 -5.87 % $ 1.29 B britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
263 K $ 8.6 -3.8 % $ 115 M usaUSA
Curis Curis
CRIS
-17 M $ 0.77 1.89 % $ 4.86 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA